期刊
CLINICAL CANCER RESEARCH
卷 14, 期 7, 页码 2042-2048出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-07-1520
关键词
-
类别
资金
- NCI NIH HHS [P20 CA101936-05, R01 CA098380-02, R01 CA098380-05, P20 CA101936-01, P20 CA101936-03, P20 CA101936, P20 CA101936-02, R01 CA098380, P20 CA101936-04, R01 CA098380-03, P30 CA016672, R01 CA098380-04, CA16672] Funding Source: Medline
Purpose: The goals of this study were to determine if single-nucleotide polymorphisms in DNA damage repair genes and cell cycle regulating genes affect clinical response to combined gemcitabine radiation therapy and the overall survival (OS) of patients with pancreatic cancer. Experimental Design: We evaluated six single-nucleotide polymorphisms of the ATM, ATM and Rad3-related (ATR), CHEK1, and CHEK2 genes in 119 patients with potentially resectable pancreatic cancer who were enrolled in clinical trials at The University of Texas M. D. Anderson Cancer Center from February 1999 toJanuary 2006, with follow-up until February 2007. Patients received neoadjuvant concurrent gemcitabine and radiation therapy with or without gemcitabine-cisplatin induction therapy. Genotypes were determined and tested for associations with OS by Kaplan-Meier estimation, the log-rank test, and Cox regression analysis. P values of <= 0.05 were considered significant. Results: The ATM G60A and CHEK1 G35A genotypes were significant (P < 0.05), and the ATR C340T genotype borderline significantly (P = 0.079) associated with OS. The hazard ratio of CHEV 35AA was 2.01 (95% confidence interval, 1.20-3.37; P = 0.007) compared with CHEV 35GG/GA with adjustments for race, sex, diabetes status, CA19-9 level, and success of tumor resection. A significant combined genotype effect was observed between ATM 60GA/GG, ATR 340CT/CC, and CHEV 35AA with median OS times of 31.0,16.2, and 10.5 months for patients carrying <= 1, 2, and 3 deleterious alleles, respectively (P = 0.004). Conclusions: These observations suggest that polymorphic variations of DNA damage response genes affect clinical response to gemcitabine radiation therapy and OS of patients with resectable pancreatic cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据